|
|
|
|
| LEADER |
02849nam a2200373Ia 4500 |
| 001 |
10.1016-j.jlr.2022.100193 |
| 008 |
220706s2022 CNT 000 0 und d |
| 020 |
|
|
|a 00222275 (ISSN)
|
| 245 |
1 |
0 |
|a Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses
|
| 260 |
|
0 |
|b American Society for Biochemistry and Molecular Biology Inc.
|c 2022
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1016/j.jlr.2022.100193
|
| 520 |
3 |
|
|a Triglyceride (TG)-lowering LPL variants in combination with genetic LDL-C-lowering variants are associated with reduced risk of coronary artery disease (CAD). Genetic variation in the APOA5 gene encoding apolipoprotein A-V also strongly affects TG levels, but the potential clinical impact and underlying mechanisms are yet to be resolved. Here, we aimed to study the effects of APOA5 genetic variation on CAD risk and plasma lipoproteins through factorial genetic association analyses. Using data from 309,780 European-ancestry participants from the UK Biobank, we evaluated the effects of lower TG levels as a result of genetic variation in APOA5 and/or LPL on CAD risk with or without a background of reduced LDL-C. Next, we compared lower TG levels via APOA5 and LPL variation with over 100 lipoprotein measurements in a combined sample from the Netherlands Epidemiology of Obesity study (N ¼ 4,838) and the Oxford Biobank (N ¼ 6,999). We found that lower TG levels due to combined APOA5 and LPL variation and genetically-influenced lower LDL-C levels afforded the largest reduction in CAD risk (odds ratio: 0.78 (0.73-0.82)). Compared to patients with genetically-influenced lower TG via LPL, genetically-influenced lower TG via APOA5 had similar and independent, but notably larger, effects on the lipoprotein profile. Our results suggest that lower TG levels as a result of APOA5 variation have strong beneficial effects on CAD risk and the lipoprotein profile, which suggest apo A-V may be a potential novel therapeutic target for CAD prevention. © 2022 THE AUTHORS
|
| 650 |
0 |
4 |
|a cardiovascular disease
|
| 650 |
0 |
4 |
|a clinical data
|
| 650 |
0 |
4 |
|a factorial analysis
|
| 650 |
0 |
4 |
|a hyperlipidemia
|
| 650 |
0 |
4 |
|a LDL genetic variation
|
| 650 |
0 |
4 |
|a lipid-lowering therapy
|
| 650 |
0 |
4 |
|a lipoprotein lipase
|
| 650 |
0 |
4 |
|a lipoproteins
|
| 650 |
0 |
4 |
|a triglycerides
|
| 700 |
1 |
0 |
|a Boot, M.
|e author
|
| 700 |
1 |
0 |
|a Christodoulides, C.
|e author
|
| 700 |
1 |
0 |
|a Dollé, M.E.T.
|e author
|
| 700 |
1 |
0 |
|a Ibi, D.
|e author
|
| 700 |
1 |
0 |
|a Jukema, J.W.
|e author
|
| 700 |
1 |
0 |
|a Karpe, F.
|e author
|
| 700 |
1 |
0 |
|a Koivula, R.
|e author
|
| 700 |
1 |
0 |
|a Neville, M.J.
|e author
|
| 700 |
1 |
0 |
|a Noordam, R.
|e author
|
| 700 |
1 |
0 |
|a Rensen, P.C.N.
|e author
|
| 700 |
1 |
0 |
|a Rosendaal, F.R.
|e author
|
| 700 |
1 |
0 |
|a van Dijk, K.W.
|e author
|
| 773 |
|
|
|t Journal of Lipid Research
|
